CEFA-LAK DIN 02173263
Status: Marketed
Holder: BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.
Molecule: CEPHAPIRIN (CEPHAPIRIN SODIUM)
Health Canada record
| Active ingredient(s) | CEPHAPIRIN (CEPHAPIRIN SODIUM) 200 MG |
|---|---|
| Dosage form | Suspension |
| Route | Intramammary |
| Schedule | PRESCRIPTION |
| Class | Veterinary |
| ATC | |
| Original market date | 22-Feb-2002 |
| Current status date | 19-Dec-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Boehringer Ingelheim (Canada) Ltd Ltee — licence 100187, currently licensed, last inspection rating C (2025-03-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CEPHAPIRIN (CEPHAPIRIN SODIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00845027 | CEFA-LAK INTRAMAMMARY INFUSION 20MG/ML | AYERST LABORATORIES | Suspension | CEPHAPIRIN (CEPHAPIRIN SODIUM) 20 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36783 | 2026-01-23 | Supplement to a New Drug Submission (SNDS) | Change in the manufacturing process for the drug substance, upgrades for sterility assurance. |
| 32375 | 2023-12-19 | Supplement to a New Drug Submission (SNDS) | Change in the drug product test and specification, container closure system, and addition of sterile designation |
| 26101 | 2021-06-18 | New Drug Submission (NDS) | CHANGE IN PRODUCT OWNERSIP |
| 25509 | 2021-03-23 | Supplement to a New Drug Submission (SNDS) | ADDITION OF DRUG SUBSTANCE MANUFACTURING SITE, MANUFACTURING CHANGES |
| 11650 | 2010-08-09 | New Drug Submission (NDS) | Change in ownership |
| 3488 | 2003-06-27 | New Drug Submission (NDS) | |
| 7028 | 1995-11-03 | New Drug Submission (NDS) |